Granhall C, Donsmark M, Blicher TM et al (2019) Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes
It has also been shown to suppress CCl11 and HMGB1 genes, which are markers associated with aging and neurological, cardiovascular, and immune diseases [2]
GLP-1 agonists may also help the heart pump better , improving blood flow and decreasing the risk of heart-related health problems
Do microbiome changes persist after discontinuing GLP-1 therapy
Together, these peptides may reduce stress by balancing cortisol levels and promoting relaxation
Titration changes the figure from month to month as doses step up, and the dispensing pathway, brand versus compounded, swings the number considerably